Wednesday, February 10, 2016 5:49:00 AM PDT | VentureDeal
King of Prussia, Pennsylvania -- Personalized medicine company Genomind has secured $2 million in new venture equity investment, according to an SEC filing.
Genomind has developed a noninvasive test for psychiatric conditions. Investors in the financing were not disclosed, nor was how the company intends to use proceeds. A total of 6 investors invested in the round as amended. The company is still seeking an additional $4 million in minimum investment increments of $250,000.
Email Page | Print Page
Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?
Start your Free 14 Day Trial now – no obligation or credit card required.
